Probiotic prophylaxis in predicted severe acute pancreatitis

The Lancet

Volumn 372, Issue 9633, 2008, Pages 112-113

  Reid, Gregor ^a   Gibson, Glenn ^b   Sanders, Mary Ellen ^c   Guarner, Francisco ^d   Versalovic, James ^e  

^a LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF READING   (United Kingdom)

^c DAIRY AND FOOD CULTURE TECHNOLOGIES   (United States)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ECOLOGIC 641; PROBIOTIC AGENT;

ACUTE PANCREATITIS; ANTIINFLAMMATORY ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; IMMUNOMODULATION; INCIDENCE; INTESTINE ISCHEMIA; LETTER; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

EID: 46949102675     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61024-7     Document Type: Letter

References (3)

1. Besselink M., van Santvoort H., Buskens E., et al., for the Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371 (2008) 651-659
2. Food and Agriculture Organization of the United Nations and World Health Organization Working Group. Guidelines for the evaluation of probiotics in food (2002), FAO/WHO, Rome/Geneva. ftp://ftp.fao.org/es/esn/food/wgreport2.pdf (accessed Feb 14, 2008)
3. Besselink M., Timmerman H., Buskens E., et al. Probiotic prophylaxis in patients with predicted severe acute pancreatitis (PROPATRIA): design and rationale of a double-blind, placebo-controlled randomised multicenter trial. BMC Surg 4 (2004) 12